Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3516084 | 1.00 | AGTR2 (1.00) | AGTR2TACR1 | |
| SCHEMBL7389164 | 0.89 | AGTR2 (0.79) | AGTR2TACR1 | |
| SCHEMBL7384730 | 0.89 | AGTR2 (0.79) | AGTR2TACR1 | |
| SCHEMBL7384728 | 0.89 | AGTR2 (0.79) | AGTR2TACR1 | |
| SCHEMBL7389160 | 0.89 | AGTR2 (0.79) | AGTR2TACR1 | |
| SCHEMBL3515166 | 0.84 | AGTR2 (0.72) | AGTR2TACR1 | |
| SCHEMBL21311846 | 0.83 | AGTR2 (0.70) | AGTR2TACR1 | |
| SCHEMBL21311950 | 0.83 | AGTR2 (0.70) | AGTR2TACR1 | |
| SCHEMBL3518039 | 0.83 | TACR1 (0.92) | TACR1 | |
| SCHEMBL3514906 | 0.83 | TACR1 (1.00) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115843246-A | Methods and compositions for treating hemangiomas | 吉利斯麦金德研究院 | 2023-03-24 | — | — | CN | disclosed |
| US-20230090708-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEMANGIOMA | MASSEY VENTURES LIMITED (NZ) | 2023-03-23 | — | — | US | disclosed |
| EP-4096648-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEMANGIOMA | Gillies Mcindoe Research Institute (NZ) | 2022-12-07 | — | — | EP | disclosed |
| US-20210395231-A1 | RECEPTOR INHIBITORS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2021-12-23 | — | — | US | disclosed |
| EP-3760620-A1 | RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USAGE THEREOF | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2021-01-06 | — | — | EP | disclosed |
| WO-2019161781-A1 | RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USAGE THEREOF | 北京泰德制药股份有限公司 | 2019-08-29 | — | — | WO | disclosed |
| EP-1830869-B1 | METHOD OF TREATMENT OR PROPHYLAXIS | SPINIFEX PHARM PTY LTD (AU) | 2013-05-22 | — | — | EP | disclosed |
| US-6218414-B1 | ADMINISTERING AN EFFECTIVE AMOUNT OF AN ANGIOTENSIN II ANTAGONIST AND A BENZOFURAN DERIVATIVE WITH ANTIARRHYTHMIC ACTIVITY FOR THERAPY OF CARDIOVASCULAR COMPLAINTS | SANOFI (FR) | 2001-04-17 | — | — | US | disclosed |
| US-5292726-A | N,N-diacylpiperazines | MERCK & CO., INC. (US) | 1994-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395231-A1 | RECEPTOR INHIBITORS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND USE THEREOF | TACR1, TACR2, GPBAR1 | AGTR2 13/4885TACR1 1/4885 |
| US-20230090708-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEMANGIOMA | AGTR2, AGTR1, AGT | AGTR2 1/4885TACR1 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.